Literature DB >> 20549647

Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers.

Brechtje A Grotenhuis1, Winand N M Dinjens, Bas P L Wijnhoven, Petra Sonneveld, Andrea Sacchetti, Patrick F Franken, Herman van Dekken, Hugo W Tilanus, J Jan B van Lanschot, Riccardo Fodde.   

Abstract

Accumulating evidence has suggested that tumours have a hierarchical organization in which only the cancer stem cells (CSCs) have tumour-initiating properties. Several surface antigens have been employed to isolate CSCs from various malignancies, although not from oesophageal adenocarcinoma (EA). We tested whether Barrett's oesophagus (BE) and EA might serve as a model for the CSC concept. In vivo assays were performed by transplantation of serially diluted bulk EA cells into NOD-SCID mice to establish the presence and frequency of tumour-initiating cells. These were found to be present as ca. 1 in 64 000 cells. The transplanted tumours fully recapitulated the primary lesions. Subsequently, a panel of previously established CSC markers was employed for immunohistochemistry. CD24, CD29 and CD44 showed heterogeneous staining in EA. Nuclear beta-catenin accumulation increased during progression from metaplasia to dysplasia and was often observed in the basal compartment with CD24 and CD29 staining. However, the overall staining patterns were not such to clearly point out specific candidate markers. Accordingly, all markers were employed to sort the corresponding subpopulations of cancer cells and transplant them at low multiplicities in NOD-SCID mice. No increased tumour-initiating capacity of sorted EA cells was observed upon transplantation. These results indicate that tumour-initiating cells are present in EA, thus reflecting a hierarchical organization. However, antibodies directed against novel surface antigens are needed to detect subpopulations enriched for CSCs in EA by transplantation assays.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549647     DOI: 10.1002/path.2733

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Kenneth J Vega; Randal May; Sripathi M Sureban; Stan A Lightfoot; Dongfeng Qu; Alessandra Reed; Nathaniel Weygant; Rama Ramanujam; Rhonda Souza; Mohammad Madhoun; Joshua Whorton; Shrikant Anant; Stephen J Meltzer; Courtney W Houchen
Journal:  J Gastroenterol Hepatol       Date:  2012-04       Impact factor: 4.029

Review 2.  Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.

Authors:  Kuancan Liu; Tingting Zhao; Junkai Wang; Yunyun Chen; Rui Zhang; Xiaopeng Lan; Jianwen Que
Journal:  Cancer Lett       Date:  2019-05-21       Impact factor: 8.679

3.  Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers.

Authors:  Giang Huong Nguyen; Mandi M Murph; Joe Y Chang
Journal:  Cancers (Basel)       Date:  2011-03       Impact factor: 6.639

Review 4.  Store-Operated Calcium Entry and Its Implications in Cancer Stem Cells.

Authors:  Isaac Jardin; Jose J Lopez; Jose Sanchez-Collado; Luis J Gomez; Gines M Salido; Juan A Rosado
Journal:  Cells       Date:  2022-04-13       Impact factor: 7.666

5.  Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.

Authors:  Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

6.  CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells.

Authors:  Pilar Jiménez; Eduardo Chueca; María Arruebo; Mark Strunk; Estela Solanas; Trinidad Serrano; María A García-González; Ángel Lanas
Journal:  Front Pharmacol       Date:  2017-05-30       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.